Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) Trial

被引：0

作者：

Marcusa, Dan P.

Giugliano, Robert P.

Park, Jeong-Gun

Sever, Peter

Wang, Huei

Hamer, Andrew

Pedersen, Terje R.

Keech, Anthony C.

Sabatine, Marc S.

机构：

来源：

CIRCULATION | 2020年 / 142卷

关键词：

D O I：

10.1161/circ.142.suppl_3.13200

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A13200

引用

页数：3

共 50 条

[31] A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
Kotowski, IK
Pertsemlidis, A
Luke, A
Cooper, RS
Vega, GL
Cohen, JC
Hobbs, HH
AMERICAN JOURNAL OF HUMAN GENETICS, 2006, 78 (03) : 410 - 422
[32] Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease
Stein, Evan A.
MAYO CLINIC PROCEEDINGS, 2009, 84 (04) : 307 - 309
[33] Low low-density lipoprotein cholesterol and cancer risk
Strandberg, Timo E.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) : 91 - 92
[34] Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk
Zafar, Kamran
Inayat, Maimoona
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 439 - 440
[35] Approach to patients with elevated low-density lipoprotein cholesterol levels
Feingold, Kenneth R.
Chait, Alan
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (03)
[36] MODELLING THE US POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL
Sanchez, Robert
Nasir, Khurram
Klimchak, Alexa
Kuznik, Andreas
Joulain, Florence
Briggs, Andrew
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 66 - 66
[37] Was the Low-Density Lipoprotein Cholesterol Level Really Elevated?
Citkowitz, Elena
LIVER TRANSPLANTATION, 2011, 17 (10) : 1234 - 1234
[38] Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: The high-density lipoprotein cholesterol story
Meagher E.A.
Current Cardiology Reports, 2004, 6 (6) : 457 - 463
[39] Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Filippatos, Theodosios D.
Kei, Anastazia
Rizos, Christos V.
Elisaf, Moses S.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (01) : 3 - 12
[40] PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity Reply
Koren, Michael J.
Sabatine, Marc S.
JAMA CARDIOLOGY, 2017, 2 (10) : 1169 - 1169

← 1 2 3 4 5 →